Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

▎药明康德内容团队编辑PTCTherapeutics今日宣布，与诺华（Novartis）签署了一项关于亨廷顿病项目PTC518及其相关分子的独家全球许可与合作协议。根据协议，PTC将获得10亿美元的预付款，以及高达19亿美元的开发、监管和销售里程碑款 ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...

Novartis will be gaining exclusive global rights to PTC Therapeutics’ mid-stage Huntington’s disease (HD) programme in a deal ...

Novartis could pay close to $3 billion for brain drugs developed by PTC Therapeutics, per a deal announced Monday. At the ...

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Key Takeaways Shares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion ...